Reviewing Cronos Group (CRON) and Its Competitors

Cronos Group (NASDAQ:CRON) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Cronos Group to related companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Valuation and Earnings

This table compares Cronos Group and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cronos Group	$146.59 million	-$9.45 million	18.05
Cronos Group Competitors	$3.56 billion	$3.19 billion	555.10

Cronos Group’s rivals have higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cronos Group and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	1	3	1	3.00
Cronos Group Competitors	7798	13888	25778	1037	2.41

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 36.29%. As a group, “Pharmaceuticals” companies have a potential upside of 25.67%. Given Cronos Group’s rivals higher probable upside, analysts clearly believe Cronos Group has less favorable growth aspects than its rivals.

Risk and Volatility

Cronos Group has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Cronos Group’s rivals have a beta of -3.71, suggesting that their average stock price is 471% less volatile than the S&P 500.

Profitability

This table compares Cronos Group and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	28.04%	2.56%	2.44%
Cronos Group Competitors	-2,380.38%	-217.94%	-15.54%

Summary

Cronos Group beats its rivals on 7 of the 13 factors compared.

Cronos Group Company Profile

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.